Skip Navigation
Search Menu
Find a Doctor


Photo of Dr. Paul Ladenson

Paul Ladenson, M.D.

Director, Division of Endocrinology & Metabolism, Department of Medicine
Professor of Medicine

Male  | Languages: English, French

Appointment Phone


Main Location

Johns Hopkins Outpatient Center

Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-7683 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »


  • Director, Division of Endocrinology & Metabolism, Department of Medicine
  • John Eager Howard Professor of Endocrinology & Metabolism
  • Professor of Medicine
  • Professor of Oncology
  • Professor of Pathology
  • Professor of Radiology and Radiological Science

Centers & Institutes



Johns Hopkins Outpatient Center

Appointment Phone: 410-955-9270

601 N. Caroline Street
Baltimore, MD 21287 map
Phone: 410-502-4926
Fax: 410-367-2042


Diagnostic Radiology, Thyroid Disorders

Research Interests

Cardiac actions of thyroid hormone; Thyroid cancer; Thyroid hormone analogs

    Additional Information

  • Education +


    • Harvard Medical School / MD (1975)


    • Massachusetts General Hospital / Medicine (1977)


    • Massachusetts General Hospital / Medicine (1978)


    • American Board of Internal Medicine / Endocrinology and Metabolism (1981)
    • American Board of Internal Medicine / Internal Medicine (1978)
  • Research & Publications +

    Research Summary

    Dr. Ladensons research relates to clinical application of novel diagnostic and prognostic markers that could improve recognition and management of thyroid cancer, and new chemotherapeutic approaches to metastatic thyroid cancer.

    Selected Publications

    Journal Citations

    Ladenson PW, Braverman LE, Mazzaferri EL, Robbins J, Cooper DS, Garber JS, Wondisford FE, Davies TF, DeGroot LJ, Daniels GH, Ross DS, Levis S, Hay ID, McEllin K, Moscicki R, Weintraub BD. Comparison of recombinant human thyrotropin administration to thyroid hormone withdrawal for radioactive iodine scanning in patients with thyroid carcinoma. New Engl J Med 1997;337:888-96.

    Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Samuels M, Graham K, Braverman LE, Skarulis M, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Becker DV, Maxon HR, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC. A comparison of recombinant thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999;84:3877-3885.

    Xing M, Tufano RP, Tufaro AP, Basaria S, Byrne PJ, Wang J, Sidransky D, Ladenson PW. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab. 2004;89:2867-72.

    Shattuck TM, Westra WH, Ladenson PW, Arnold A. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. New Engl J Med 2005;352:2406-2412.

    Xing M, Westra WH, M.D., Tufano RP, Rosenbaum E, Cohen Y, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz ME, Tufaro AP, Califano JA, Ringel MD., Zeiger MA., Sidransky D, and Ladenson PW. BRAF mutation predicts a poorer prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90:6373-9.

    Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos R, Sherman S, Haugen B, Corone C, Molinaro E, Elisei, Ceccarelli C, Pinchera A, Wahl R, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin
    Endocrinol Metab 2006;91:926-32.

    Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Schuff KG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Weintraub BD, Ridgway EC, Ladenson PW. A Comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with rhTSH compared to thyroid hormone withdrawal. J Clin Endocrinol Metab 2006;91:878-84.

    Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Corone C, Jacene HA, Ewertz ME, Bournaud C, Wahl RL, Sherman SI, Ladenson PW, Schlumberger M. Assessment of the Incremental Value of Recombinant TSH Stimulation before FDG PET/CT Imaging to Localize Residual Differentiated Thyroid Cancer J Clin Endocrinol Metab 2009;94:1310-1316.

    Hu, S.; Ewertz, M.; Tufano, R.P.; Brait, M.; Carvalho, A.L.; Liu, D.; Tufaro, A.P.; Basaria, S.; Cooper, D.S.; Sidransky, D.; Ladenson, P.W.; Xing, M. Detection of serum deoxyribonucleic acid methylation markers: a novel diagnostic tool for thyroid cancer. J Clin Endocrinol Metab. 2006 Jan;91(1):98-104.

    Sgouros, G.; Song, H.; Ladenson, P.W.; Wahl, R.L. Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule. J Nucl Med. 2006 Dec;47(12):1977-1984.

    Song, H.; He, B.; Prideaux, A.; Du, Y.; Frey, E.; Kasecamp, W.; Ladenson, P.W.; Wahl, R.L.; Sgouros, G. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J Nucl Med. 2006 Dec;47(12):1985-1994.

    Diaz, L.A., Jr.; Foss, C.A.; Thornton, K.; Nimmagadda, S.; Endres, C.J.; Uzuner, O.; Seyler, T.M.; Ulrich, S.D.; Conway, J.; Bettegowda, C.; Agrawal, N.; Cheong, I.; Zhang, X.; Ladenson, P.W.; Vogelstein, B.N.; Mont, M.A.; Zhou, S.; Kinzler, K.W.; Vogelstein, B.; Pomper, M.G. Imaging of musculoskeletal bacterial infections by [124I]FIAU-PET/CT. PLoS One. 2007;2(10):e1007.

    Prideaux, A.R.; Song, H.; Hobbs, R.F.; He, B.; Frey, E.C.; Ladenson, P.W.; Wahl, R.L.; Sgouros, G. Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. J Nucl Med. 2007 Jun;48(6):1008-1016.

    Hobbs, R.F.; Wahl, R.L.; Lodge, M.A.; Javadi, M.S.; Cho, S.Y.; Chien, D.T.; Ewertz, M.E.; Esaias, C.E.; Ladenson, P.W.; Sgouros, G. 124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison. J Nucl Med. 2009 Nov;50(11):1844-1847.

    Jonklaas, J.; Cooper, D.S.; Ain, K.B.; Bigos, T.; Brierley, J.D.; Haugen, B.R.; Ladenson, P.W.; Magner, J.; Ross, D.S.; Skarulis, M.C.; Steward, D.L.; Maxon, H.R.; Sherman, S.I. Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid. 2010 Dec;20(12):1423-1424.

    Ladenson, P.W. Thyroid Hormone Analogues: Ready for Prime Time. Thyroid. 2010 Dec 27;21(2):101-102.

    Ladenson, P.W.; Kristensen, J.D.; Ridgway, E.C.; Olsson, A.G.; Carlsson, B.; Klein, I.; Baxter, J.D.; Angelin, B. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med. 2010 Mar 11;362(10):906-916.

  • Academic Affiliations & Courses +
  • Activities & Honors +
  • Videos & Media +
Is This You? Edit Profile